Summary
In an open study dl-phenylalanine in doses from 75–200 mg/day was administered to 20 depressed patients for 20 days.
Patients were classified according to the International Classification of Diseases (ICD).
The AMP system, the Hamilton depression scale and the von Zerssen self rating questionnaire were used for documentation of psychopathological, neurologic and somatic changes. In addition a global clinical impression was agreed upon by experienced psychiatrists.
At the end of the trial 12 patients (8 with complete, 4 with good response) could be discharged without any further treatment. 4 patients with partially untypical depressions experienced mild to moderate responses, whereas 4 patients did not respond at all to the phenylalanine administration. Depressive “core symptoms” as depressed mood, retardation and/or agitation were preferentially, anxiety and sleep disturbances moderately and hypochondriasis and compulsiveness were not influenced.
It is concluded that dl-phenylalanine might have substantial antidepressant properties and that further more controlled investigations are warranted.
Similar content being viewed by others
References
Angst, J., Battegay, R., Bente, D., Berner, P., Broeren, W., Heimann, H., Engelmeier, P. H., Cornu, F., Dick, P., Hippius, H., Poeldinger, W., Schmidlin, P., Schmitt, W., Weiss, P. Dokumentationssystem der Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie. (AMP) Arzneim.-Forsch. (Drug Res.)19, 399–405 (1969).
Birkmayer, W. Experimentelle Befunde und neue Aspekte bei extrapyramidalen Erkrankungen. Wiener Zeitschr. f. Nervenheilkunde13, 128–139 (1966).
Boulton, A., Milward, L. Separation, detection and quantitative analysis of urinary beta-phenylethylamine. J. Chromatogr.57, 287–296 (1971).
Beckmann, H. Saavedra, J. M.: Urinary excretion of phenylethylamine in depressed patients and healthy controls. (In preparation.)
Cotzias, G. C., Van Woert, M. H., Schiffer, L. M. Aromatic amino acids and modification of parkinsonism. New Engl. J. Med.276, 374–379 (1967).
Cramer, H. Zur Inkorporation von3H-Phenylalanin in Proteine der circumventrikulären Organe bei Katzen und Meerschweinchen. Autoradiographische Untersuchung. Exp. Brain Res.11, 343–359 (1970).
Fischer, E., Heller, B., Miró, A. N. β-Phenylethylamine in human urine. Arzneim.-Forsch. (Drug Res.)18, 1486 (1968).
Fischer, E., Spatz, H., Saavedra, J. M., Reggiani, H., Miró, A. H., Heller, B. Urinary elimination of phenethylamine. Biol. Psychiat.5, 139 (1972).
Fischer, E., Spatz, H., Heller, B., Reggiani, H. Phenylethylamine content of human urine and rat brain, its alteration in pathological conditions and after drug administration. Experientia28, 307 (1972).
Fischer, E., Spatz, H., Fernández Labriola, R. S., Rodriguez Casanova, E. M., Spatz, N. Quantitative gas-chromatographic determination and infrared spectrographic identification of urinary phenethylamine. Biol. Psychiat.7, 161–165 (1973).
Fischer, E., Heller, B., Nacbon, M., Spatz, H. Therapy of depression by phenylalanine. Arzneim.-Forsch. (Drug Res.)25, 132 (1975).
Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiat.23, 56–61 (1960).
Heller, B., Fischer, E. Diminution of phenethylamine in the urine of Parkinson patients. Arzneim.-Forsch.23, 884–886 (1973).
International classification of diseases. 8. Revision. WHO, Public. No 8921, Geneva 1974. New York-Heidelberg-Berlin: Springer. 1975.
Inwang, E. E., Mosnaim, A. D., Sabelli, H. C. Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. J. Neurochem.20, 1469–1473 (1973).
Jepson, J. B., Lovenberg, W., Zaltzman, P. Amine metabolism studied in normal and phenylketonuric humans by monoamine oxidase inhibition. J. Biochem.74, 5 (1960).
Kalinowsky, L. B., Hippius, H. Pharmacological, convulsive and other somatic treatments in psychiatry. New York-London: Grune and Stratton. 1968.
Lovenberg, W., Weissbach, H., Udenfriend, S. Aromatic L-amino acid decarboxylase. J. Biol. Chem.237, 89–97 (1962).
Mosnaim, A. D., Sabelli, H. C. Quantitative determination of the brainlevels of aβ-phenylethyl-amine-like substance in control and drug-treated mice. Pharmacologist13, 283–294 (1971).
Mosnaim, A. D., Inwang, E. E., Sugarman, J. H., DeMartini, W. J., Sabelli, H. C. Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat.3, 235–257 (1973).
Mosnaim, A. D., Inwang, E. E., Sugarman, J. H., Sabelli, H. C. Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression. Biol. Psychiat.6, 235–242 (1973).
Morris, J. B., Beck, A. T. The efficacy of antidepressant drugs. A review of research (1958–1972). Arch. Gen. Psychiat.30, 667–674 (1974).
Saavedra, J. M. Enzymatic isotopic assay for and presence of beta-phenyl-ethylamine in brain. J. Neurochem.22, 211–216 (1974).
Sabelli, H. C., Giardina, W. J., Mosnaim, D. A., Sabelli, N. H. A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system. Acta Physiol. Pol.24, 33–40 (1973).
Sabelli, H. C., Mosnaim, A. D. Phenylethylamine hypothesis of affective behavior. Am. J. Psychiat.131, 695–699 (1974).
Spatz, H., Heller, B., Nachon, M., Fischer, E. Effects of d-phenylalanine in clinical picture and phenetylaminuria in depression. Biol. Psychiat.10, 235–238 (1975).
Winer, B. J. Statistical principles in experimental design. New York: McGraw-Hill. 1971.
Yang, H.-Yt., Neff, N. H. Monoamine oxidase: I. A natural substrate for type B enzyme. Feration Proc.32, 797 (1973).
von Zerssen, D., Strian, F., Schwarz, D. Evaluation of depressive states, especially in longitudinal studies. In: Psychological measurements in psychopharmacology. Modern problems of pharmacopsychiatry, 7 (Pichot, P., Olivier-Martin, R., eds.), pp. 189–202. Basel-München-Paris: Karger. 1974.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beckmann, H., Strauss, M.A. & Ludolph, E. Dl-phenylalanine in depressed patients: An open study. J. Neural Transmission 41, 123–134 (1977). https://doi.org/10.1007/BF01670277
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01670277